2.04BMarket Cap
LossP/E TTM
NKTR Balance Sheet
You can check out the annual or quarterly balance sheets of Nektar Therapeutics here to evaluate the financial health, analyze fundamentals, and calculate key ratios for liquidity, leverage, and return on equity.
FAQs
Which balance sheet metrics matter most when analyzing NKTR stock?
Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.
What is the difference between assets, liabilities, and shareholders' equity?
Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.
What is the difference between current and non-current items?
Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.
How Much Cash Does Nektar Therapeutics Have?
In its most recent quarterly, Nektar Therapeutics had 149.58M in cash and cash equivalents.
How Much Are Nektar Therapeutics's Total Liabilities?
Nektar Therapeutics reported 190.57M in total liabilities as of the latest reported quarter, including 53.54M in current liabilities and 137.04M in non-current liabilities.
What Are Nektar Therapeutics's Total Assets?
As of the latest reported quarter, Nektar Therapeutics's total assets were 280.41M, consisting of 266.27M in current assets and 14.14M in non-current assets.
How Much Shareholders' Equity Does Nektar Therapeutics Have?
Nektar Therapeutics reported 89.83M in total shareholders' equity as of the latest reported quarter.